Effectiveness of a Videoconference-Based Cognitive Behavioral Therapy Program for Patients with Schizophrenia: Pilot Randomized Controlled Trial

Overview

Journal JMIR Form Res

Publisher JMIR Publications

Specialty Biomedical Engineering

Date 2024 Nov 29

PMID 39610049

Authors

Masayuki Katsushima

Hideki Nakamura

Yuki Shiko

Hideki Hanaoka

Eiji Shimizu

Affiliations

Soon will be listed here.

Abstract

Background: Cognitive behavioral therapy for psychosis (CBTp) is not sufficiently widespread in clinical practice, although evidence has been presented.

Objective: The purpose of this study was to explore whether one-on-one videoconference-based CBTp (vCBTp) is more effective than usual care (UC) alone for improving psychiatric symptoms in patients with schizophrenia attending outpatient clinics.

Methods: In this exploratory randomized controlled trial, patients with schizophrenia and schizoaffective disorders who were still taking medication in an outpatient clinic were randomly assigned to either the vCBTp plus UC group (n=12) or the UC group (n=12). The vCBTp program was conducted once a week, with each session lasting for 50 minutes, for a total of 7 sessions conducted in real-time and in a one-on-one format remotely using a loaned tablet computer (iPad). The primary outcome was the Positive and Negative Syndrome Scale (PANSS) total score, which measures the difference in the mean change from baseline (week 0) to posttest (week 8).

Results: The study included 24 participants. There were no significant differences between the 2 groups at baseline. With regard to significant differences between the 2 groups in terms of the primary outcome, the mean change in the PANSS total score from baseline to week 8 in the vCBTp plus UC group was -9.5 (95% CI -12.09 to -6.91) and the mean change in the UC alone group was 6.9 (95% CI 1.54-12.30). The difference between the 2 groups was significant (P<.001). In addition, significant improvements were observed in the subscales of positive (P<.001) and negative (P=.004) symptoms and general psychopathology (P<.001). Significant differences were also observed in the secondary outcomes of the General Anxiety Disorder-7 (GAD-7; P=.04) and EQ-5D-5L (P=.005). There were no dropouts and no serious adverse events in this study.

Conclusions: A total of 7 remote vCBTp sessions conducted in the vCBTp plus UC group could be safely administered to patients with schizophrenia. They were also observed to be effective for psychiatric symptoms, general anxiety, and quality of life. However, because of the observed worsening of scores in the UC group, caution is required in interpreting significant differences between the 2 groups. This approach is expected to improve accessibility to CBTp for outpatients with schizophrenia and social anxiety regarding transportation use and financial and physical burdens related to transportation, and to contribute to promoting CBTp acceptability by compensating for the shortage of implementers.

Trial Registration: University Hospital Medical Information Network Clinical Trials Registry UMIN000043396; https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000049544.

International Registered Report Identifier (irrid): RR2-10.1136/bmjopen-2022-069734.

References

Spitzer R, Kroenke K, Williams J, Lowe B . A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006; 166(10):1092-7. DOI: 10.1001/archinte.166.10.1092. View

Santesteban-Echarri O, Piskulic D, Nyman R, Addington J . Telehealth interventions for schizophrenia-spectrum disorders and clinical high-risk for psychosis individuals: A scoping review. J Telemed Telecare. 2018; 26(1-2):14-20. DOI: 10.1177/1357633X18794100. View

Szymczynska P, Walsh S, Greenberg L, Priebe S . Attrition in trials evaluating complex interventions for schizophrenia: Systematic review and meta-analysis. J Psychiatr Res. 2017; 90:67-77. DOI: 10.1016/j.jpsychires.2017.02.009. View

Hedman E, Ljotsson B, Lindefors N . Cognitive behavior therapy via the Internet: a systematic review of applications, clinical efficacy and cost-effectiveness. Expert Rev Pharmacoecon Outcomes Res. 2012; 12(6):745-64. DOI: 10.1586/erp.12.67. View

Menon M, Andersen D, Quilty L, Woodward T . Individual factors predicted to influence outcome in group CBT for psychosis (CBTp) and related therapies. Front Psychol. 2015; 6:1563. PMC: 4623397. DOI: 10.3389/fpsyg.2015.01563. View

Ruegg N, Moritz S, Berger T, Ludtke T, Westermann S . An internet-based intervention for people with psychosis (EviBaS): study protocol for a randomized controlled trial. BMC Psychiatry. 2018; 18(1):102. PMC: 5899332. DOI: 10.1186/s12888-018-1644-8. View

Bighelli I, Huhn M, Schneider-Thoma J, Krause M, Reitmeir C, Wallis S . Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis. BMC Psychiatry. 2018; 18(1):380. PMC: 6280425. DOI: 10.1186/s12888-018-1964-8. View

ODriscoll C, Mason O, Brady F, Smith B, Steel C . Process analysis of trauma-focused cognitive behavioural therapy for individuals with schizophrenia. Psychol Psychother. 2015; 89(2):117-32. DOI: 10.1111/papt.12072. View

Sin J, Spain D, Furuta M, Murrells T, Norman I . Psychological interventions for post-traumatic stress disorder (PTSD) in people with severe mental illness. Cochrane Database Syst Rev. 2017; 1:CD011464. PMC: 6464771. DOI: 10.1002/14651858.CD011464.pub2. View

10.

Mueser K, McGurk S . Schizophrenia. Lancet. 2004; 363(9426):2063-72. DOI: 10.1016/S0140-6736(04)16458-1. View

11.

Taguchi K, Numata N, Takanashi R, Takemura R, Yoshida T, Kutsuzawa K . Clinical Effectiveness and Cost-effectiveness of Videoconference-Based Integrated Cognitive Behavioral Therapy for Chronic Pain: Randomized Controlled Trial. J Med Internet Res. 2021; 23(11):e30690. PMC: 8663446. DOI: 10.2196/30690. View

12.

Ventura J, Nuechterlein K, Lukoff D, Hardesty J . A prospective study of stressful life events and schizophrenic relapse. J Abnorm Psychol. 1989; 98(4):407-11. DOI: 10.1037//0021-843x.98.4.407. View

13.

Hazell C, Hayward M, Cavanagh K, Strauss C . A systematic review and meta-analysis of low intensity CBT for psychosis. Clin Psychol Rev. 2016; 45:183-92. DOI: 10.1016/j.cpr.2016.03.004. View

14.

Asukai N, Kato H, Kawamura N, Kim Y, Yamamoto K, Kishimoto J . Reliability and validity of the Japanese-language version of the impact of event scale-revised (IES-R-J): four studies of different traumatic events. J Nerv Ment Dis. 2002; 190(3):175-82. DOI: 10.1097/00005053-200203000-00006. View

15.

Gunnmo P, Bergman H . What do individuals with schizophrenia need to increase their well-being. Int J Qual Stud Health Well-being. 2011; 6(1). PMC: 3091845. DOI: 10.3402/qhw.v6i1.5412. View

16.

Morrison A, Law H, Carter L, Sellers R, Emsley R, Pyle M . Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. Lancet Psychiatry. 2018; 5(5):411-423. PMC: 6048761. DOI: 10.1016/S2215-0366(18)30096-8. View

17.

Hall P, Tarrier N . The cognitive-behavioural treatment of low self-esteem in psychotic patients: a pilot study. Behav Res Ther. 2003; 41(3):317-32. DOI: 10.1016/s0005-7967(02)00013-x. View

18.

Tai S, Turkington D . The evolution of cognitive behavior therapy for schizophrenia: current practice and recent developments. Schizophr Bull. 2009; 35(5):865-73. PMC: 2728828. DOI: 10.1093/schbul/sbp080. View

19.

Woods S . Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003; 64(6):663-7. DOI: 10.4088/jcp.v64n0607. View

20.

Na P, Yaramala S, Kim J, Kim H, Goes F, Zandi P . The PHQ-9 Item 9 based screening for suicide risk: a validation study of the Patient Health Questionnaire (PHQ)-9 Item 9 with the Columbia Suicide Severity Rating Scale (C-SSRS). J Affect Disord. 2018; 232:34-40. DOI: 10.1016/j.jad.2018.02.045. View